MedTrace Logo

Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography

NCT00942981 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 283

Last updated 2026-05-22

No results posted yet for this study

Summary

Background:

* Some illnesses, such as schizophrenia, have effects on brain cells called dopamine receptors, which are required for normal brain function. People with schizophrenia have difficulty thinking and experience hallucinations and delusions. Medications that change brain dopamine receptors can decrease these hallucinations and delusions.
* The cause of schizophrenia and its association with brain dopamine receptors is not known but may be clarified by studying dopamine receptors in people who have dopamine disorders (such as schizophrenia) and those who do not. Researchers are interested in studying the dopamine system to gain a better idea of how dopamine disorders develop, which may lead to better medical care for people with schizophrenia.

Objectives:

\- To study the amount and distribution of two types of dopamine receptors.

Eligibility:

* Individuals between the ages of 18 and 60 who have schizophrenia.
* Healthy volunteers between the ages of 18 and 90.

Design:

* Participants will undergo a full screening, with physical and psychological history, a neurological examination, and blood and urine samples.
* Participants will have a blood flow map of the brain recorded with a positron emission tomography (PET) brain scan. A magnetic resonance imaging (MRI) scan will also be performed to determine brain anatomy.
* To study the amount and distribution of dopamine receptors in the brain, participants will receive a small amount of a radioactive chemical in the vein, followed by a PET scan.
* The procedure will be performed twice in two separate sessions, once for \[18F\]fallypride and once for \[11C\]NNC-112.

Conditions

Interventions

DRUG

PET

Brain dopamine D1 and D2/3 receptor regional binding potentials measured by \[11C\]NNC-112 and \[18F\]Fallypride PET.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Principal Investigators

  • Karen F Berman, M.D. · National Institute of Mental Health (NIMH)

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00942981 on ClinicalTrials.gov